

Resource Summary Report

Generated by [kravitz2](#) on Jul 30, 2026

phCMV-GALV-MTR

RRID:Addgene_163612

Type: Plasmid

Proper Citation

RRID:Addgene_163612

Plasmid Information

URL: <http://www.addgene.org/163612>

Proper Citation: RRID:Addgene_163612

Insert Name: GaLV MTR envelope

Organism: Other

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:31586074](#)

Vector Backbone Description: Backbone Marker:Addgene 15802; Backbone Size:4764; Vector Backbone:phCMV-ECO-ENV; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: This plasmid was generated by modification of Addgene plasmid 15802 to excise ENV-Eco and replace with ENV GALV-MTR.

Plasmid Name: phCMV-GALV-MTR

Record Creation Time: 20220422T221925+0000

Record Last Update: 20260725T074147+0000

Ratings and Alerts

No rating or validation information has been found for phCMV-GALV-MTR.

No alerts have been found for phCMV-GALV-MTR.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Varano G, et al. (2025) B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements. *Blood cancer discovery*, 6(4), 364.

Sagou K, et al. (2024) Epstein-Barr virus lytic gene BNRF1 promotes B-cell lymphomagenesis via IFI27 upregulation. *PLoS pathogens*, 20(2), e1011954.

Bristol JA, et al. (2024) Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice. *PLoS pathogens*, 20(4), e1012132.

Hoang NM, et al. (2024) Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma. *Cell reports. Medicine*, 5(4), 101484.

Mlynarczyk C, et al. (2023) BTG1 mutation yields supercompetitive B cells primed for malignant transformation. *Science (New York, N.Y.)*, 379(6629), eabj7412.

Bristol JA, et al. (2022) Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. *PLoS pathogens*, 18(4), e1010453.

Qazilbash MH, et al. (2022) A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. *Blood*, 139(9), 1289.